Login to Your Account

TKT Says It Will No Longer Seek U.S. Replagal Approval

By Kim Coghill

Wednesday, January 14, 2004
Transkaryotic Therapies Inc. lost 23.5 percent of its stock value after announcing its decision to abandon efforts to win U.S. approval of Replagal, an enzyme replacement therapy for Fabry's disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription